Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Says Another COVID-19 Test Thrown Off By Omicron Variant

Executive Summary

The US FDA has added the Linea COVID-19 Assay Kit to its list of diagnostics that could produce false-negative results due to the most recent coronavirus mutation.

You may also be interested in...



Another COVID-19 Diagnostic Impacted By Omicron Variant

The Revogene SARS-CoV-2 test from Meridian Bioscience could give false-negative results because of the latest coronavirus variant. The good news is that the diagnostic hasn’t been distributed in the US, the FDA says.

COVID-19 Omicron Variant Could Cause False-Negative Results In Tide Labs Test, FDA Says

The US FDA said this week that the DTPM COVID-19 RT-PCR Test made by Tide Laboratories LLC could give erroneous readings because of the latest coronavirus variant.

Some Essential Cardiac Devices In Short Supply, FDA Warns

The US Food and Drug Administration is alerting health care providers that some cardiac devices from a major supplier are in short supply.

 

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT144845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel